Polio Vaccines

Global Polio Vaccines Market to Reach US$979.2 Million by 2030

The global market for Polio Vaccines estimated at US$809.0 Million in the year 2024, is expected to reach US$979.2 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Inactivated Polio Vaccine, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$624.0 Million by the end of the analysis period. Growth in the Oral Polio Vaccine segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$220.4 Million While China is Forecast to Grow at 5.9% CAGR

The Polio Vaccines market in the U.S. is estimated at US$220.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$192.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Polio Vaccines Market – Key Trends & Drivers Summarized

Why Do Polio Vaccines Remain a Cornerstone of Global Public Health Despite Near-Eradication?

Polio vaccines have been the foundation of one of the most ambitious global public health campaigns ever undertaken—aiming to eliminate poliomyelitis, a crippling and potentially fatal infectious disease caused by the poliovirus. Despite significant progress, with wild poliovirus now endemic in only a few countries, continued vaccination remains critical due to risks of re-emergence, vaccine-derived poliovirus strains, and global mobility. Two primary vaccine types—oral polio vaccine (OPV) and inactivated polio vaccine (IPV)—remain central to immunization strategies in different regions depending on transmission risk, healthcare infrastructure, and regulatory frameworks.

OPV, particularly the bivalent (bOPV) and novel oral polio vaccine type 2 (nOPV2), is widely used in mass immunization campaigns due to its ease of administration and ability to confer community protection through gut immunity and viral shedding. IPV, on the other hand, is preferred in high-income countries and in routine immunization schedules for its safety profile and lack of risk for vaccine-derived strains. As the global health community transitions to a polio endgame strategy, the co-administration of IPV and nOPV2 is being prioritized to ensure immunity, prevent outbreaks, and achieve long-term eradication.

How Are Technological Advancements and Strategic Formulations Enhancing Vaccine Efficacy and Safety?

Vaccine R&D has evolved to develop safer and more stable polio vaccines with improved immunogenicity and a lower risk of circulating vaccine-derived poliovirus (cVDPV). The introduction of nOPV2, engineered with genetically stabilized attenuation profiles, represents a breakthrough in addressing the challenges posed by type 2 poliovirus outbreaks linked to earlier OPV formulations. This vaccine is being deployed under WHO’s Emergency Use Listing and has shown promising early field results in limiting the emergence of neurovirulent revertants.

Advances in cold chain logistics, freeze-drying, and prefilled injectable formats have further expanded the reach and shelf life of polio vaccines, particularly in remote or conflict-affected regions. Combination vaccines incorporating IPV with diphtheria, pertussis, and tetanus (DPT-IPV) are gaining traction in routine immunization programs for their efficiency and broader coverage. The use of digital immunization registries, barcoded vials, and geospatial mapping in immunization campaigns is also improving traceability, monitoring, and data-driven deployment, thereby enhancing vaccination efficacy and accountability.

Which Global Alliances and Regional Programs Are Driving Polio Vaccine Distribution and Coverage?

The Global Polio Eradication Initiative (GPEI)—led by WHO, UNICEF, the U.S. CDC, Rotary International, and the Bill & Melinda Gates Foundation—has been the primary driver of vaccine funding, coordination, and field deployment for over three decades. National immunization days (NIDs), door-to-door campaigns, and outbreak response immunization efforts (ORIs) have all played pivotal roles in raising global polio vaccine coverage. Countries with weak health infrastructure or conflict zones remain priority areas, requiring targeted campaigns and cross-border coordination.

South Asia and sub-Saharan Africa have historically been focal points for vaccine delivery, although most regions have now transitioned from trivalent OPV (tOPV) to bOPV and IPV. Afghanistan and Pakistan remain the last strongholds of wild poliovirus, necessitating ongoing surveillance and high-frequency immunization drives. In developed regions such as North America and Europe, IPV is standard in national immunization schedules, with focus now shifting to bolstering preparedness and maintaining herd immunity. As global eradication inches closer, regional surveillance and sustained vaccine uptake will be essential to prevent resurgence.

What Is Driving Long-Term Strategic Focus and Innovation in the Polio Vaccines Market?

The growth in the polio vaccines market is driven by ongoing global eradication efforts, emergence of cVDPV outbreaks, and international health security mandates. While eradication may ultimately reduce the size of the routine polio vaccine market, short- to medium-term demand is expected to remain high due to emergency responses, transition plans, and stockpile requirements. Governments and NGOs are committed to maintaining high coverage and vaccine stockpiles to ensure polio’s irreversible elimination.

Strategically, manufacturers are investing in next-generation IPV production using Vero cell and Sabin strain platforms to increase biosafety and reduce production costs. Technology transfers and local manufacturing initiatives—especially in India, Indonesia, and parts of Africa—are enhancing regional supply chain resilience. Public-private partnerships, pooled procurement by UNICEF and Gavi, and continued innovation in vaccine packaging and delivery are reinforcing the global vaccination infrastructure. As the polio endgame approaches, the vaccine market will pivot from volume-based supply to a strategic reserve-driven, precision-deployment model aimed at complete and sustained eradication.

SCOPE OF STUDY:

The report analyzes the Polio Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Inactivated Polio Vaccine, Oral Polio Vaccine); End-Use (Hospitals & Clinics End-Use, Public Services End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Adithya Vaccine Pharma
• Astellas Pharma Inc.
• Beijing Tiantan Biological Products Corp
• Bharat Biotech International Ltd.
• Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)
• Bio Farma
• Bio-Med Healthcare Products Pvt. Ltd.
• Biomed-Lublin
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline (GSK)
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more